Secondary Cancer Risk Is Low After CAR-T Cell Treatment: Stanford Study

Results of a large Stanford Medicine study, published Wednesday in The New England Journal of Medicine, finds CAR-T therapies carry a low risk of secondary malignancies not related to the CAR-T cells.